KOSDAQBiotech & Pharma046210

HLB Panagene

₩1,250 0.00%2026-10-02 close

Market Cap

₩56B

Turnover

₩300M

Volume

240,000 shares

Shares out.

45.5M

PER

—

PBR

0.7×

EPS

-₩74

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

HLB Panagene: PNA Technology Expansion Meets Consolidated Losses

HLB Panagene continues to expand its business around proprietary Peptide Nucleic Acid (PNA) technology and overseas certifications, but consolidated operating losses have persisted for three straight years, diverging sharply from the standalone-basis profits the company has reported.

1
Consolidated revenue rose to KRW 15.0 billion in 2025 from the prior year, but operating losses have continued for three consecutive years since 2023.
2
On a standalone basis, the company reported operating profit in 2024, 2025, and the first half of 2026.
3
Built on its proprietary PNA technology, the company is expanding from diagnostic materials and products into next-generation nucleic acid therapeutics such as Antibody-Oligonucleotide Conjugates (AOC).
4
The company is working toward completing its European IVDR transition while expanding overseas markets through its US partner, ChemGenes.
5
In June 2026, HLB Group chairman Jin Yang-gon was disclosed to have added shares of HLB Panagene among his additional purchases of group affiliate stocks.

Business structure

HLB Panagene is a Daejeon-based KOSDAQ-listed biotech company and an affiliate of HLB Group that develops and manufactures molecular diagnostic reagents and materials based on its proprietary Peptide Nucleic Acid (PNA) technology.

The company developed its own Bts monomer technology to enable high-quality mass synthesis of PNA, and on this basis has built multiple generations of molecular diagnostic platforms including PNAClamp, AssiProbe, and PANA RealTyper.

The company states that it has built a vertically integrated structure spanning materials, biology, and precision manufacturing, including its own extraction equipment.

Its diagnostic products are used mainly in oncology and infectious disease testing, and the company has secured 38 European CE certifications (including 11 under IVDR) and 93 health-authority approvals worldwide, expanding registrations into emerging markets such as Pakistan.

Through its subsidiary Biosquare, the company is broadening its diagnostics portfolio, and in October 2025 obtained export manufacturing approval from Korea's Ministry of Food and Drug Safety for the 'NanoPACK HIV 1/2 Ab' in-vitro diagnostic device for HIV infection.

More recently, the company has begun developing Antibody-Oligonucleotide Conjugates (AOC) using its PNA technology, extending its business into next-generation nucleic acid therapeutics pipelines.

In the US market, the company works with its PNA distribution partner ChemGenes to build connections with local drug developers and CDMO companies. On a standalone basis, the company states it exports PNA materials and diagnostic products to more than 50 countries.

Earnings trend

Quarterly revenue · Operating profit

₩3.6B-₩200M25Q2₩3.6B-₩800M25Q3₩4.2B-₩1.7B25Q4₩3.1B-₩700M26Q1₩3.7B-₩200M26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩14.2B₩1.6B2022₩12.3B-₩1.8B2023₩13.2B-₩1.4B2024₩15B-₩3.4B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩3.6B	-₩200M	−5.5%
2025Q3	₩3.6B	-₩800M	−22.8%
2025Q4	₩4.2B	-₩1.7B	−39.6%
2026Q1	₩3.1B	-₩700M	−23.9%
2026Q2	₩3.7B	-₩200M	−4.3%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩14.2B	₩1.6B	₩2.2B	11.1%	7.1%	9.4%
2023	₩12.3B	-₩1.8B	-₩4.8B	−15.0%	−7.6%	43.0%
2024	₩13.2B	-₩1.4B	-₩1.9B	−10.3%	−2.6%	44.0%
2025	₩15B	-₩3.4B	-₩3.1B	−22.9%	−4.3%	28.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

Consolidated revenue declined from KRW 14.2 billion in 2022 to KRW 12.3 billion in 2023, then recovered to KRW 13.2 billion in 2024 and KRW 15.0 billion in 2025.

Consolidated operating profit, however, swung from a KRW 1.58 billion gain in 2022 to losses of KRW 1.84 billion in 2023, KRW 1.36 billion in 2024, and KRW 3.44 billion in 2025, with the loss widening for three straight years.

Net income attributable to owners also deteriorated sharply from a KRW 2.24 billion gain in 2022 to a KRW 4.82 billion loss in 2023, narrowed to a KRW 1.94 billion loss in 2024, then widened again to a KRW 3.13 billion loss in 2025. Quarterly results show considerable volatility.

In Q3 2025 revenue was KRW 3.64 billion with an operating loss of KRW 0.83 billion and a net loss of KRW 0.16 billion; in Q4 2025 revenue reached a quarterly peak of KRW 4.23 billion, yet the operating loss widened to KRW 1.68 billion and the net loss expanded sharply to KRW 3.59 billion.

In Q1 2026, revenue fell to KRW 3.13 billion with an operating loss of KRW 0.75 billion and a net loss of KRW 1.07 billion, while Q2 2026 saw revenue of KRW 3.71 billion, a narrower operating loss of KRW 0.16 billion, and owners' net income turning positive at KRW 1.55 billion.

The periods in which net income turned positive despite operating losses (KRW 1.21 billion in Q2 2025 and KRW 1.55 billion in Q2 2026) appear to reflect non-operating items whose impact is not fully explained by operating performance alone.

Separately, the company reported that on a standalone (non-consolidated) basis it generated operating profit in 2024, 2025, and the first half of 2026, highlighting a gap between the standalone figures and the consolidated losses, which reflect the impact of subsidiary results.

The balance sheet showed improvement as the debt ratio rose from 9.4% in 2022 to 43-44% in 2023-2024 before falling to 28.3% in 2025, while operating cash flow swung from small surpluses of KRW 0.04 billion in 2023 and KRW 0.35 billion in 2024 to a net outflow of KRW 0.64 billion in 2025.

Industry analysis

Global market research firm The Insight Partners forecast that the nucleic acid therapeutics market would grow from roughly USD 8.03 billion in 2025 to about USD 25.85 billion by 2034, a compound annual growth rate of 15.74%.

The company states that PNA offers advantages over conventional DNA and RNA materials in target-binding strength, sequence discrimination, and stability.

This market growth outlook coincides with renewed interest in PNA materials for drug development pipelines, and the company presented the characteristics of PNA relative to PMO, which is used in existing oligonucleotide therapeutics, at a US industry conference.

In molecular diagnostics, the transition to Europe's strengthened In Vitro Diagnostic Regulation (IVDR) is imposing certification cost and time burdens across the industry, though the company has stated a goal of completing this transition within the year.

The global diagnostics market remains highly competitive with numerous participants, but the vertically integrated combination of proprietary PNA source material technology and in-house extraction equipment is cited as a differentiator held by only a small number of companies.

The AOC (Antibody-Oligonucleotide Conjugate) field remains at an early stage, with HLB Panagene and numerous other companies competing to establish platforms.

Outlook

In an interview, CEO Jang In-geun outlined a goal of transforming the company into a 'total solution diagnostic platform' provider and stated an aim of raising the share of overseas revenue to 50% within three years.

The company plans to complete its European IVDR transition within the year to solidify its market position under the strengthened regulatory framework.

In September 2026, the company delivered the opening keynote on PNA technology at the 'Oligonucleotides & Peptides Xchange 2026' conference in San Francisco, and held one-on-one meetings with global drug developers and CDMO companies alongside its partner ChemGenes during the event.

The CEO stated that the event confirmed strong interest from global drug developers in the technical characteristics and practical application potential of PNA. The company set a goal of accelerating AOC development in the second half of the year to produce more tangible results.

Expanding the diagnostics product portfolio through collaboration with subsidiary Biosquare was also presented as part of its second-half strategy.

Valuation

PER

—

PBR

0.7×

ROE

-4.3%

EPS

-₩74

BPS

₩1,547

Dividend per share

₩0

On a self-calculated basis, the current share price trades at a discount to net asset value. Because the trailing four quarters combined show a net loss, multiples based on net income are difficult to compute in this window.

Dividends have not been paid recently, so rather than dividend appeal, the pace of earnings recovery and balance sheet improvement remain the key variables for valuation assessment.

Given a trajectory that included a profitable year in 2022 followed by a return to losses, whether the company can move out of consolidated losses going forward may serve as an important reference point for assessing its trading level relative to net asset value.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

Proprietary PNA Technology and Vertical Integration

HLB Panagene developed the world's first PNA mass-production technology and established a high-quality synthesis foundation through its own Bts monomer technology. Its vertically integrated structure, spanning materials, extraction equipment, and diagnostic products, is cited as a differentiator from competitors.

The company has built multiple generations of diagnostic platforms such as PNAClamp along with a global certification base including 38 European CE approvals.

Expanding Global Certifications and Export Network

The company has secured 93 health-authority approvals worldwide, including the registration of eight cancer diagnostic kits in Pakistan. Subsidiary Biosquare obtained export manufacturing approval for an HIV diagnostic kit in October 2025.

On a standalone basis, the company exports PNA materials and diagnostic products to more than 50 countries, and in the US it is expanding partnerships with drug developers through ChemGenes.

Improving Balance Sheet and Insider Buying

The debt ratio improved from 43-44% in 2023-2024 to 28.3% in 2025, indicating a strengthening balance sheet. The company reported maintaining standalone operating profit in 2024, 2025, and the first half of 2026.

In June 2026, HLB Group chairman Jin Yang-gon made additional open-market purchases of 14,562 HLB Panagene shares, increasing his holdings to 405,373 shares.

Bear factors

Widening Consolidated Losses

Consolidated operating losses have continued for three straight years since 2023, widening from KRW 1.84 billion in 2023 to KRW 3.44 billion in 2025. Net losses of KRW 3.59 billion and KRW 1.07 billion were recorded in Q4 2025 and Q1 2026, respectively, reflecting high earnings volatility.

The coexistence of standalone-basis profit and consolidated-basis losses makes it difficult to gauge how subsidiary results are affecting overall performance.

Small-Cap Liquidity Characteristics

HLB Panagene is classified as a small-cap KOSDAQ stock, and its trading volume and supply-demand dynamics can be heavily influenced by factors beyond earnings fundamentals.

The recent weighted-average number of shares outstanding was about 47.54 million, with market capitalization relatively modest relative to the share float. This small-cap characteristic is cited as a factor that can amplify share price volatility.

Early-Stage Risk in AOC and New Businesses

AOC (Antibody-Oligonucleotide Conjugate) development remains at an early research stage, and commercialization may require substantial time and expense.

The company has set a goal of producing more tangible results in the second half of the year, but specific commercialization timelines or partnership scale have not yet been disclosed.

Drug development carries greater risk than the existing diagnostics and materials businesses due to uncertainty around clinical and regulatory outcomes.

Risk factors

Earnings Volatility

Operating profit and net income show large quarter-to-quarter swings, and non-operating items have a significant impact on net income, making earnings difficult to forecast. As in Q4 2025, periods can occur where net losses widen even as revenue rises.

Investors need to check quarter by quarter for differences between consolidated and standalone figures and for one-off items.

Overseas Regulatory and Certification Risk

Stricter overseas certification rules such as Europe's IVDR entail cost and time burdens, and delays in the transition could limit market access for exported products. Registration procedures in emerging markets also vary by country, which could delay certification timing.

Pipelines such as AOC are also exposed to uncertainty around domestic and international clinical and approval regulations.

Affiliate and Governance Risk

As an HLB Group affiliate, HLB Panagene's investment sentiment can be influenced by group-wide issues or events at other affiliates.

Share transactions by the largest shareholder or related parties are facts confirmed through disclosures, and their impact on the share price should be interpreted on a case-by-case basis.

Where business synergies or financial support relationships exist among affiliates, it can become harder to assess an individual company's performance independently.

What to watch next

Mid-November 2026
Check whether preliminary Q3 2026 results are disclosed and whether the consolidated operating profit and net income trend continues the improvement seen in Q2.
Q4 2026 (by year-end)
Monitor whether the European IVDR transition is completed within the year as planned and track changes in related certification counts.
From Q4 2026 onward
Watch for disclosures of follow-up partnering or technology transfer related to AOC development, and whether the company's stated goal of tangible second-half results materializes.
Ongoing
Track whether contracts are signed with US drug developers or CDMO companies through the ChemGenes partnership, and monitor additional overseas certification or registration disclosures.

Overall view

HLB Panagene operates a molecular diagnostics materials and products business built on proprietary PNA technology, is expanding its infectious disease diagnostics portfolio through subsidiary Biosquare, and has recently extended into next-generation nucleic acid therapeutics such as AOC.

Consolidated revenue fluctuated between 2022 and 2025 before recovering to KRW 15.0 billion in 2025, but operating losses have continued for three straight years since 2023 with the loss widening, and net income attributable to owners has shown large quarterly swings.

In contrast, the company has reported maintaining standalone-basis operating profit since 2024, and the debt ratio improved in 2025, showing signs of balance sheet strengthening as well.

Multiple items to monitor going forward, including the European IVDR transition, the ChemGenes partnership in the US market, and AOC development, remain key variables that will shape future performance and business direction.

Investors should consider together the gap between consolidated and standalone figures, the impact of quarterly non-operating items, and the pace of commercialization for new businesses. This report is intended for informational purposes only and does not constitute a buy or sell recommendation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.